Pacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to “Hold”

ValuEngine upgraded shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a sell rating to a hold rating in a report published on Wednesday.

PCRX has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a buy rating to a hold rating in a report on Monday, October 9th. Canaccord Genuity reiterated a buy rating and issued a $44.00 price target (down previously from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. Wedbush reiterated an outperform rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Needham & Company LLC reiterated a buy rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Finally, BidaskClub lowered shares of Pacira Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, January 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $49.00.

Shares of Pacira Pharmaceuticals (PCRX) traded down $0.73 on Wednesday, hitting $41.50. 1,031,870 shares of the company’s stock were exchanged, compared to its average volume of 712,847. The firm has a market cap of $1,683.66, a price-to-earnings ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. Pacira Pharmaceuticals’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business earned $0.20 EPS. equities research analysts anticipate that Pacira Pharmaceuticals will post -0.85 EPS for the current year.

In other news, CAO Kristen Marie Williams sold 10,000 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the completion of the transaction, the chief executive officer now directly owns 159,164 shares in the company, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. In the last three months, insiders sold 98,960 shares of company stock worth $3,868,341. Insiders own 6.60% of the company’s stock.

Several hedge funds have recently modified their holdings of PCRX. Schwab Charles Investment Management Inc. increased its stake in Pacira Pharmaceuticals by 8.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 178,700 shares of the company’s stock worth $8,524,000 after buying an additional 13,973 shares during the period. Rhumbline Advisers increased its stake in Pacira Pharmaceuticals by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 49,203 shares of the company’s stock worth $2,347,000 after buying an additional 1,672 shares during the period. SG Americas Securities LLC increased its stake in Pacira Pharmaceuticals by 135.6% during the 2nd quarter. SG Americas Securities LLC now owns 6,395 shares of the company’s stock worth $305,000 after buying an additional 3,681 shares during the period. Bank of New York Mellon Corp increased its stake in Pacira Pharmaceuticals by 5.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,087 shares of the company’s stock worth $10,403,000 after buying an additional 11,652 shares during the period. Finally, Legal & General Group Plc increased its stake in Pacira Pharmaceuticals by 5.3% during the 2nd quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock worth $620,000 after buying an additional 653 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to “Hold”” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/pacira-pharmaceuticals-pcrx-upgraded-by-valuengine-to-hold.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply